Lymphoma & Plasma Cell Disorders
From the Journals
TP53 mutations could help stratify MCL patients
The study looks at response to standard-of-care regimens in younger patients.
From the Journals
Lenalidomide shows clinical activity in relapsed/refractory MCL
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
FDA approves brentuximab vedotin for pcALCL, MF
The US Food and Drug Administration (FDA) has expanded the approved use of brentuximab vedotin (BV, ADCETRIS). BV is now approved for adults with...
News
FDA approves IV formulation of aprepitant for CINV
The US Food and Drug Administration (FDA) has approved use of an intravenous (IV) formulation of aprepitant (CINVANTI™) to prevent chemotherapy-...
News
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphoma
Approval was based on a 56% objective response rate for brentuximab vedotin vs. 12% for physician’s choice of methotrexate or bexarotene in a...
Conference Coverage
Ibrutinib sustains efficacy in CLL at 4-year follow-up
NEW YORK, NY—The 4-year follow-up of the RESONATE trial suggests ibrutinib may provide long-term efficacy in previously treated patients with...
Conference Coverage
Intervention improves well-being in AYAs with cancer
SAN DIEGO—New research suggests an intervention can improve psychosocial health in adolescents and young adults (AYAs) living with cancer. The...
News
Cancer drug costs increasing despite competition
Cancer drug costs in the US increase substantially after launch, regardless of competition, according to a study published in the Journal of...
Conference Coverage
Cancer patients prefer computer-free interactions
SAN DIEGO—A new study suggests patients with advanced cancer may prefer doctors who do not use a computer while communicating with them. Most of...
From the Journals
Event-free survival at 24 months predicts outcomes in peripheral T-cell lymphomas
Event-free survival at 24 months (EFS24) is predictive of survival in patients with peripheral T-cell lymphomas (PTCLs), according to new findings...
News
FDA approves drug to treat rel/ref MCL
The US Food and Drug Administration (FDA) has granted accelerated approval to the BTK inhibitor acalabrutinib (Calquence, formerly ACP-196). The...